[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354072-105":59,"doc-detail-354072-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","plasticity-signaling-and-metabolic-rewiring-in-melanoma-persister-cells","Plasticity, signaling, and metabolic rewiring in melanoma persister cells","","Despite advances in melanoma therapy, metastatic disease still has poor survival outcomes, with drug-tolerant persister cells enabling recurrence. This review synthesizes evidence that persister traits emerge from both preexisting phenotypes and drug-induced adaptations, linked by “primed” intermediate states. Compared with parental, stem-like, and senescent variants, persisters show reversible differentiation program changes, distinct metabolic rewiring, and altered signaling networks shaped by the tumor microenvironment. It identifies knowledge gaps and proposes priorities for persister-directed interventions toward clinical translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plasticity-signaling-and-metabolic-rewiring-in-melanoma-persister-cells/354072/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plasticity-signaling-and-metabolic-rewiring-in-melanoma-persister-cells/354072.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do melanoma persister cells matter for recurrence and treatment failure?","Question",{"text":112,"@type":113},"Drug-tolerant persisters can survive therapy and facilitate cancer recurrence, including through contributions to minimal residual disease (MRD). Their traits differ from parental cells and vary with context and treatment strategy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What mechanisms drive the formation of melanoma persisters?",{"text":117,"@type":113},"Persisters can originate from rare preexisting cells with intrinsic survival traits, from drug-induced adaptations via epigenetic and metabolic reprogramming, or from “primed” persisters in intermediate states that predispose tolerance.",{"name":119,"@type":110,"acceptedAnswer":120},"How do persisters differ from other melanoma cell phenotypes?",{"text":121,"@type":113},"Melanoma persisters display altered but reversible differentiation programs, distinct metabolic adaptations (e.g., shifts in glycolysis and oxidative phosphorylation pathways), and rewired signaling networks influenced by the tumor microenvironment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354072,1790766366,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","communications biology Review article  \nA Nature Portfolio journal  \n[https://doi.org/10.1038/s42003-026-10143-w](https://doi.org/10.1038/s42003-026-10143-w)  \nPlasticity, signaling, and metabolic rewiring in melanoma persister cells  \n Check for updates  \nShayne Sensenbach 1, Han G. Ngo1,2 & Mehmet A. Orman 1,2   \nDespite advances in therapy, survival rates for metastatic melanoma remain low. Drug-tolerant persister cells (persisters) can facilitate cancer recurrence, yet their characteristics and vulnerabilities differ across cancers and even within melanoma, depending on mutational context and treatment strategy. Both preexisting phenotypic traits and drug-induced adaptations contribute to persister formation, linked by “primed” persisters that exhibit intermediate states observed in multiple studies. Compared with parental melanoma cells and other phenotypic variants such as melanoma stem cells or senescent cells, persisters show altered and reversible differentiation programs, distinct metabolic adaptations, and rewired signaling networks, all affected by the tumor microenvironment, but remain poorly understood. This review focuses on melanoma persisters, highlighting advances in understanding their origins, signaling plasticity, metabolic rewiring, and therapeutic vulnerabilities. By identifying gaps, this review further provides much-needed recommendations for future research and outlines priorities for advancing persister-directed interventions toward clinical translation.  \nMelanoma is a pressing health concern in the United States and globally. The American Cancer Society projects 104,960 melanoma diagnoses in the United States in 2025, resulting in 8430 deaths1. Incidence rates for melanoma have risen over the past several decades2, and recurrence rates above 40%have been reported for metastatic melanoma3. Most melanoma tumors harbor oncogenic mutations in the rapidly accelerated ﬁbrosarcoma B-type (BRAF) gene, speciﬁcallyBRAFV600E mutations, which drive continuous, uncontrolled proliferation4,5. Therefore, targeted therapeutics that block this oncogenic pathway, including BRAF and mitogen-activated protein kinase (MEK) inhibitors (BRAFi and MEKi, respectively), are widely used to treat metastatic melanoma6. Prior to the discovery of these modern therapeutics, traditional chemotherapeutics were the only option, and these drugs are ineffective in melanoma6. While BRAFi and MEKi have drastically improved response rates in melanoma, recurrence and the development of drug resistance mechanisms are nearly certain for advanced cases6–8.  \nPersistence, a transient form of drug tolerance, is an important phenomenon related to cancer recurrence and treatment failure in general.“Persisters” were originally discovered in bacterial cultures in the1940s, and they were characterized as a rare, slow-or non-growing sub-population of cells that tolerate antibiotic treatment9, 10. More recently, the slow-or nongrowing, drug-tolerant phenotype was also discovered in sub-populations of cancer cells, and these cells are known as cancer persisters11–13. Clinically, these cancer persisters are thought to contribute to minimal residual disease (MRD) and recurrence11–14, and the contribution of persisters to these phenomena has been demonstrated in animal experiments15. Cancer  \npersisters have been discovered in many cancer types upon treatment with various anticancer agents, including traditional chemotherapeutics and targeted therapeutics11–13. However, the characteristics of cancer persisters vary depending on the cell type, mutational status, and the treatment strategy used. Additionally, persisters are especially important in melanoma treatment, due to the high rates of recurrence in melanoma3, as well as the high levels of genetic and epigenetic diversity shown in melanomas compared to other cancers16–18.  \nSeveral recent review articles have focused broadly on melanoma, summarizing the treatment methods and the challenges posed by t","cbCaieJJF6LILlbK","https://ap.wps.com/l/cbCaieJJF6LILlbK","pdf",1526417,12,"English","# Overview of melanoma persisters: origins, plasticity, and metabolic rewiring\n## Origins of Persisters\n## Phenotypic Plasticity and Signaling\n## Metabolic Rewiring","[{\"question\":\"Why do melanoma persister cells matter for recurrence and treatment failure?\",\"answer\":\"Drug-tolerant persisters can survive therapy and facilitate cancer recurrence, including through contributions to minimal residual disease (MRD). Their traits differ from parental cells and vary with context and treatment strategy.\"},{\"question\":\"What mechanisms drive the formation of melanoma persisters?\",\"answer\":\"Persisters can originate from rare preexisting cells with intrinsic survival traits, from drug-induced adaptations via epigenetic and metabolic reprogramming, or from “primed” persisters in intermediate states that predispose tolerance.\"},{\"question\":\"How do persisters differ from other melanoma cell phenotypes?\",\"answer\":\"Melanoma persisters display altered but reversible differentiation programs, distinct metabolic adaptations (e.g., shifts in glycolysis and oxidative phosphorylation pathways), and rewired signaling networks influenced by the tumor microenvironment.\"}]","Plasticity, signaling, and metabolic rewiring in melanoma persister cells | PDF",1790108737,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6af469d9915d21c6815b1c764ef94171.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47be418e7166ea092494b2e78f82c5d6.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91c79988ab96aa38a69e947b98b428b0.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb216a36b79dd6702dbdfad9d5455871.webp",980,1301]